We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

By LabMedica International staff writers
Posted on 12 Dec 2022

Lupus erythematosus (LE) is a severe autoimmune disease characterized by the presence of many abnormal immune cells and a large number of autoantibodies and immune complexes, all of which lead to damage to multiple organs, such as the skin, kidney, and brain. More...

Discoid lupus erythematosus (DLE) and systemic lupus erythematosus (SLE) are both types of lupus, yet the characteristics, and differences between them are not fully understood. Cutaneous lupus erythematosus (CLE), which mainly presents as dermatological injuries and does not involve systemic damage. Discoid lupus erythematosus (DLE) accounts for >80% of cases of CLE and is the most common type of CLE.

A team of Dermatologists at the Central South University (Changsha, China) and their colleagues collected 23 skin biopsy samples from eight DLE patients with an average age of 40.4 ± 11.0 years, 10 SLE patients with an average age of 41.4 ± 12.3 years and five healthy controls (HCs) with an average age of 32.4 ± 6.0 years, were collected. The scientists performed single cell RNA-Seq (scRNA-seq) on 14 epidermal single-cell suspensions (four HCs, five DLE, and five SLE samples) and 16 dermal single-cell suspensions (four HCs, five DLE, and seven SLE) by the 10× Genomics Chromium system (Pleasanton, CA, USA).

The investigators reported that they found significantly higher proportions of T cells, B cells and NK cells in DLE than in SLE. Expanded CCL20+ keratinocyte, CXCL1+ fibroblast, ISGhiCD4/CD8 T cell, ISGhi plasma cell, pDC, and NK subclusters were identified in DLE and SLE compared to HC. In addition, they observed higher cell communication scores between cell types such as fibroblasts and macrophage/dendritic cells in cutaneous lesions of DLE and SLE compared to HC. The proportions of T cells, B cells, Macro/DC, and NK cells were 29.5%, 1.7%, 10.2%, and 3.5%, respectively, in the epidermis of DLE patients, and 31.2%, 0.4%, 8.6%, and 1.9%, respectively, in the epidermis of SLE patients, which were higher than those in the epidermis of HC. In the dermis, the receptors of CCL19 (CCR7, CCR2, and CXCR3), CXCL12 (CXCR4), FAM3C (CLEX2D), and TNFSF13B (CD40) in fibroblasts showed the highest expression in B, Macro/DCs, NK, and T cells in the DLE group among the three sample groups.

The authors concluded that their findings provide much information about DLE- and SLE-specific cellular and molecular signatures in cutaneous lesions compared to that of healthy controls. They described in detail the similarities and differences in cell compositions between DLE and SLE, which will help understand the pathogenesis of DLE and SLE and develop novel and precise therapeutic targets for lupus erythematosus. The study was published on December 5 2022 in the journal Nature Communications.

Related Links:
Central South University
10× Genomics


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.